NEWS HIGHLIGHTSMedia Articles Related to Zolinza (Vorinostat)
Immune Therapy Can Protect Against Or Treat Later Lymphoma
Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today [2009.11.03]
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.
Immunotherapy Demonstrates Long-Term Success In Treating Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.31]
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research Initiative Grants
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.30]
The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.
Lymphoma Patients Benefit From Exercise
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.28]
A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found.
Pixantrone Produces High Rates Of Complete Remission In Multiple Relapsed And Refractory Indolent And Aggressive Non-Hodgkin's Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.23]
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.
Published Studies Related to Zolinza (Vorinostat)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. [2009.10.06]
BACKGROUND: Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access and binding to DNA... CONCLUSION: These findings suggest that vorinostat can be combined with weekly doxorubicin in this schedule at a dose of 800 mg day(-1). The HDAC2 expression may be a marker predictive of HDAC inhibition. Antitumor activity of this regimen in breast cancer, prostate cancer, and melanoma seems interesting.
A phase 2 study of vorinostat in acute myeloid leukemia. [2009.10]
BACKGROUND: This two-stage, multi-institutional, randomized phase 2 trial assessed the toxicity and response rate associated with two treatment schedules of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid; SAHA) in patients with relapsed acute myeloid leukemia and in selected untreated patients with high-risk acute myeloid leukemia... CONCLUSIONS: Vorinostat monotherapy demonstrated minimal activity in this group of patients with acute myeloid leukemia. Therapy was discontinued in many patients before the planned four cycles had been administered, either because of failure of vorinostat to control the leukocyte count or patients' and physicians' preference. Future studies of vorinostat in acute myeloid leukemia should focus on combinations with other drugs with which it might interact pharmacodynamically. ClinicalTrials.gov Identifier: NCT00305773.
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. [2009.09.10]
Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL). A phase I trial of oral vorinostat was conducted in Japanese patients with malignant lymphoma... These data suggest that further investigations of vorinostat in non-Hodgkin lymphoma, focusing on FL and MCL, are warranted.
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. [2009.09]
Vorinostat (suberoylanilide hydroxamic acid), a potent, oral histone deacetylase inhibitor, has demonstrated clinical activity in non-Japanese patients with various hematological and solid tumors. We sought to determine the maximum tolerated dose and a recommended phase II dose for 18 Japanese patients with solid tumors (median age, 58 years; range, 25-72 years) who failed standard therapy...
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. [2009.08.26]
BACKGROUND:: This phase 2 trial was designed to evaluate the efficacy of vorinostat in chemotherapy-pretreated patients with metastatic castration-resistant prostate cancer... CONCLUSIONS:: Vorinostat at this dose was associated with significant toxicities limiting efficacy assessment in this patient population. The significant association between IL-6 levels and removal from the study for toxicities warrants further investigation. Cancer 2009. (c) 2009 American Cancer Society.
Clinical Trials Related to Zolinza (Vorinostat)
A Phase I/II Clinical Trial of an Experimental Cancer Drug in Combination With an FDA Approved Cancer Drug for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer [Terminated]
The reason for this study will be to find the safest maximum tolerated dose of oral
vorinostat in combination with erlotinib (Tarceva (TM)) that can be given to patients with
lung cancer who have relapsed or failed other therapy for the disease. Once the safest
maximum tolerated dose of vorinostat is determined, patients enrolled in the clinical trial
will continue vorinostat and erlotinib for up to 8 months. Safety and effectiveness will also
be evaluated.
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors [Active, not recruiting]
The purpose of this investigational study is to determine the safety and tolerability of oral
suberoylanilide hydroxamic acid when administered in combination with standard doses of
pemetrexed and cisplatin for the treatment of advanced solid tumors.
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. [Recruiting]
Vorinostat (Suberoylanilide Hydroxamic Acid; NSC 701852) is a drug that inhibits an enzyme
that plays a key role in the regulation of cell survival, growth, and eventual cell death,
all of which play a role in cancer. As a result, this drug has the potential to affect a
tumor's ability to survive. Vorinostat is the most potent drug of its kind that is currently
under investigation in clinical trials. The primary objective of this study is to define the
maximum safest dose of vorinostat in combination with a standard chemotherapy agent,
docetaxel, in patients with advanced and relapsed lung, bladder, or prostate cancer.
Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [Recruiting]
The purpose of this research study is to: 1) Determine the highest dose of the drug
vorinostat that can be given safely in combination with carboplatin and gemcitabine and 2)
determine how long the participant's cancer will respond to the combination of vorinostat,
carboplatin and gemcitabine. Vorinostat is a type of drug called a histone deacetylase
inhibitor (HDAC inhibitor). HDAC inhibitors interact with chromosomes in the cancer cell
and cause cancer cells to stop growing. Vorinostat has shown a decrease in the amount of
ovarian cancer cells growing in the laboratory and also may enhance the anti-cancer effects
of carboplatin.
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer [Recruiting]
A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval
in patients with relapsed or refractory advanced cancer.
|
